Acalabrutinib with or without obinutuzumab for early CLL/SLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 trial studies whether acalabrutinib, and optionally adding obinutuzumab, can control early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to see how well these treatments work and how safe they are in people who have not had prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have either biopsy-proven SLL or CLL confirmed by specific blood test patterns.
- You have not been treated yet for CLL/SLL before starting the study (certain supplements and non-CLL steroids usually don’t count).
- Your CLL/SLL diagnosis was made less than 24 months before you register.
- Your CLL risk test (CLL-IPI) must be completed within about 2 years and the results for all required factors must be available (including IGHV if it’s part of your test).
- You must have good general health and function (ECOG performance status 0–2) and be well enough that the study team thinks treatment can be safely monitored.
- If your CLL risk is high or very high, you must meet specific blood test minimums and liver/kidney/bleeding-related lab limits, and you must provide pregnancy/cancer-cell-related safety checks if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies how well acalabrutinib works when combined with either venetoclax or obinutuzumab in people with untreated chronic lymphocytic leukemia (CLL). It aims to improve disease control while checking safety and tolerability.
This Phase 1 study tests a new combination of medicines to treat people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has not been treated before and needs therapy. It aims to shrink the disease and control it safely in this early testing stage.
This study follows people with CLL who are starting acalabrutinib (a targeted pill) for the first time, either as their first treatment or after previous therapies. The goal is to see how well it works in everyday medical practice.
This trial tests a new drug, nemtabrutinib, against two standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment yet. The goal is to see if the new drug works better at controlling the disease.
This trial tests whether adding acalabrutinib to obinutuzumab plus venetoclax works better than the standard combo (obinutuzumab plus venetoclax) for people with untreated, high-risk CLL. It’s designed to see if the stronger mix can improve control of the leukemia with an acceptable safety profile.
This trial is testing a combination of three targeted drugs (tafasitamab, acalabrutinib, and venetoclax) for people with CLL or SLL who have not yet received treatment. The goal is to see if this combination is effective and manageable.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.